Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2336)	9/7/2002 1:09:34 AM
From: limit	Respond to of 2515

At what point will you people cover?

To: Cacaito who wrote (2336)	9/8/2002 10:30:15 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 2515

Cacaito, What have you been smoking or drinking, lately? My public record on C225 and IMCL here at SI is clear and unchanged. First, I am not attacking You (maybe I should?), only method by which you are making conclusion. Even 10% response rate (accompanied with medical benefit) is something that FDA will consider very seriously. Second, it is pointless to discuss C225 with you. Eliminate IMCL from picture. It is not Sam, Peter, Joe,... who is factor in drug efficacy. It is drug by itself. <<You were wrong since the RTF came out.>> I predicted potential problems with C225 before and after 2001 ASCO, when first data of ~20% response rate in CC were reported. 8 Months before RTF. Iressa combined (two PII) response rate is ~15%. Miljenko